Pharmaceutical company Lupin has announced a non-exclusive patent licence agreement with Takeda Pharmaceutical for the ...

Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialise Vonoprazan ...

Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to ...

Lupin Ltd has signed a non-exclusive patent licence agreement with Takeda Pharmaceutical to commercialize Vonoprazan tablets ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

These factors collectively underscore Mamegano’s confidence in Takeda Pharmaceutical Co’s stock performance and the company’s robust pipeline of treatments poised for market success.

Global pharma major Lupin Limited (Lupin) announced that it has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited (Takeda), to commercialize vonoprazan ...

Lupin Limited partners with Takeda to launch Vonoprazan tablets in India, targeting acid peptic disorders with Lupivon brand.

Gene therapy research in Japan has gained significant momentum due to the SAKIGAKE designation system and government-led ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

Mobocertinib is under clinical development by Takeda Pharmaceutical and currently in Phase I for Cervical Cancer.

Mobocertinib is under clinical development by Takeda Pharmaceutical and currently in Phase I for Pancreatic Cancer.